Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Focuses on Combination Therapy of Opdivo with Chemotherapies; Development of Small-Molecule Drugs also Underway
July 25, 2017
- Mitsubishi Tanabe to Buy Israel’s NeuroDerm for US$1.1 Billion
July 24, 2017
- Gilteritinib Earns US Orphan Status for AML: Astellas
July 24, 2017
- Hemophilia A Treatment Emicizumab Filed in Japan: Chugai
July 24, 2017
- Takeda, Schrödinger Link Up on Drug Discovery
July 24, 2017
- Asahi Kasei Pharma to Expand Lineup in Orthopedic Field, Boost Osteoporosis Market Share through Once-Yearly Formulation of Reclast
July 24, 2017
- AZ Japan Facing Civil Lawsuit over Demotions, Pay Cuts
July 21, 2017
- Whistleblower Bayer Rep Raps “No Instruction” Finding in Xarelto Scandal Probe
July 21, 2017
- Takecab Most Promoted Drug for Hospital Doctors for 7th Month: Anterio
July 21, 2017
- NanoCarrier’s Micellar Nanoparticle Drug Gets FDA Orphan Status
July 20, 2017
- Kowa President Has High Hopes for Livalo Successor Parmodia
July 20, 2017
- Zymeworks Gains US$1 Million from Daiichi Sankyo in Bispecific Antibody Milestone
July 20, 2017
- Hisamitsu Begins New Japan PIII for NSAIDs Patch after Unfavorable PII/III
July 20, 2017
- Takeda-Teva JV to Discontinue Sale of 53 Generic APIs
July 19, 2017
- JCR, Teijin to Codevelop Regenerative Medicine Product, Plan to Begin Clinical Studies in 2018
July 19, 2017
- Sunovion to Divest Asthma and Allergy Products to Focus on COPD
July 18, 2017
- Bayer Yakuhin to Ban Any Type of Medical Affairs Work by Sales Organization
July 18, 2017
- Probe Finds No HQ Instruction for Improper Patient Info Acquisition in Xarelto Surveys, Bayer Execs Take 3-Month Pay Cuts
July 18, 2017
- Nichi-Iko’s Remicade Biosimilar Filed in 2 Routes, Ayumi to Also Market It under Different Trade Name
July 14, 2017
- Ambicion, RIKEN Pair Up for Joint Research to Develop Novel Antiallergics
July 14, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…